Physician profile
Joseph Poon
NPI 1174541205
$6,011.72
in general payments reported to CMS, 2019-2025
19 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,975 · 2020: $1,368 · 2021: $276 · 2022: $576 · 2023: $152 · 2024: $131 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,084.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $707.20 | 2019-2025 | Breztri, Airsupra, Lokelma |
| Gilead Sciences, INC. | $556.18 | 2019-2024 | |
| Lilly USA, LLC | $529.08 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.65 | 2019-2024 | Jardiance |
| Horizon Therapeutics Plc | $424.31 | 2019-2021 | |
| Amgen INC. | $393.00 | 2019-2025 | Repatha |
| Novo Nordisk INC | $345.72 | 2019-2025 | Wegovy |
| Amarin Pharma, INC. | $306.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $271.87 | 2020-2021 | |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $128.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.04 | 2020 | |
| Radius Health, INC. | $117.81 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $117.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.80 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.35 | 2021 | |
| Boston Scientific Corporation | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.